Recent advances in Alzheimer’s disease research continue to highlight the complexity and multifactorial nature of the disease. A recent study published in the New England Journal of Medicine (NEJM), titled Biomarker Changes during 20 Years Preceding Alzheimer’s Disease provides pivotal data showing that researchers now can accurately predict development of Alzheimer's disease more than decade earlier. While this study used spinal fluid amyloid markers we expect that new blood markers such as neurofilament light chan, P-Tau 181, and P-Tau 217 that we recently incorporated into standard clinical practice have same predictive accuracy. The importance of developing accurate predictive is monumental.

At our ReCODE program at GW Center for Integrative Medicine, we’ve been implementing a preventative and personalized approach for preventing Alzheimer's. The PreCODE program (link, https://gwcim.com/services/recode-pro... for those at high risk of Alzheimer’s—showed that over 7 years none of over 50 patients developed cognitive decline.

The NEJM findings align with what Dr. Dale Bredesen emphasizes in his work and podcast on brain health, "Talking Brain Health with Dr. Dale Bredesen". Dr. Bredesen’s approach, implemented in our PreCODE program, focuses on identifying and addressing multiple underlying contributors to cognitive decline, including inflammation, toxins, and metabolic factors, which complement the therapeutic strategies presented in the NEJM article.

This integrative approach, blending cutting-edge research and holistic treatment protocols, aims to enhance outcomes for those at risk or in the early stages of Alzheimer’s disease.

Talking Brain Health with Dr. Dale Bredesen link: https://podcasts.apple.com/us/podcast...

Other resources: https://www.nejm.org/doi/full/10.1056...